CBDBuzzz.com
  • Home
  • News
  • Culture
  • Science
  • Health
  • Videos
  • Shop
No Result
View All Result
CBDBuzzz.com
  • Home
  • News
  • Culture
  • Science
  • Health
  • Videos
  • Shop
No Result
View All Result
CBDBuzzz.com
No Result
View All Result

FDA Releases New Guidelines to Encourage Cannabis-related Research

July 21, 2020
in Science
Reading Time: 3 mins read
A A
FDA Releases New Guidelines to Encourage Cannabis-related Research
402
SHARES
2.4k
VIEWS
ShareShareShareShareShare

The United States Food and Drug Administration just gave a big boost to cannabis research. The FDA released draft guidance explaining how cannabis companies can develop cannabis drugs – and receive FDA approval for those drugs.

FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D, claims multiple stakeholders have expressed interest in developing cannabis-based drugs. Because of this growing interest, the FDA is working to support drug development in the cannabis space.

“A range of stakeholders have expressed interest in development of drugs that contain cannabis and compounds found in cannabis,” said Abernethy in her July 21 statement.

“Recent legislative changes have also opened new opportunities for cannabis clinical research. As that body of research progresses and grows, the FDA is working to support drug development in this area.”

With these goals in mind, the FDA has issued draft guidance for cannabis research, including quality considerations and other information for those conducting cannabis research.

Abernethy added that the FDA will “do what we can” to support the development of new cannabis-based drugs. The FDA believes the current drug approval process is the best way to create safe and effective new medicines for patients.

“It is critical that the FDA continues to do what we can to support the science needed to develop new drugs from cannabis. The FDA believes the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs that contain cannabis or cannabis-derived compounds, are available to patients in need of appropriate medical therapy.”

To date, critics have attacked the FDA and other organizations for discouraging cannabis-related research. United States federal drug policy makes it difficult for universities to research Schedule I substances, for example, stifling formal research towards cannabis-based drugs.

FDA Releases Draft Guidance for Cannabis Research

On July 21, the FDA issued draft guidance for the cannabis industry entitled, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry”.

You can view the full draft guidance here. It describes the FDA’s current approach to clinical cannabis research, including how manufacturers can develop new cannabis-based drugs.

The draft guidance explains things like:

  • How to obtain cannabis for clinical research
  • Quality considerations and recommendations for THC levels in medical cannabis
  • Guidelines for cannabis oil and other types of cannabis products
  • How to calculate weights for oral dosages
  • Online resources for cannabis-related clinical trials
  • Key FDA regulatory concepts for stakeholders who are unfamiliar with the FDA and its requirements

Overall, the draft guidance walks cannabis companies through the development of FDA-approved, cannabis-based drugs.

Using the draft guidance, cannabis drug developers can learn how to obtain approval, how to get research-grade cannabis, and everything else they need to know about developing cannabis-based drugs approved by the FDA.

The FDA developed its draft based on a 2019 public hearing. That hearing involved industry representatives complaining about inaccurate or misleading labels for CBD products, including the potential for contamination.

To date, the FDA has only approved one cannabis-based drug: Epidiolex, which uses a synthetic form of CBD to fight a rare type of seizure.

Moving forward, the FDA could rapidly approve more cannabis drugs that meet its requirements. The FDA can approve drugs that have a proven ability to treat or prevent illness. If a cannabis company can prove their product significantly reduces the risk of a disease, then the FDA could approve it quickly.

For now, the draft guidance makes it significantly easier for cannabis companies to develop new, FDA-approved cannabis products.

The FDA will accept comments on these rules for 60 days before writing a final version.

Credit: Source link

Share161Tweet101SendShare28Pin36
Previous Post

More evidence that cannabis helps sickle-cell symptoms

Next Post

Porn and Pot Surged During the Pandemic—But Which Performed Best?

Related Posts

How to Debunk Alleged Cannabis Harms ?
Science

How to Debunk Alleged Cannabis Harms ?

February 6, 2023
Trump says Harris ‘lied’ when questioned on cannabis (Newsletter: August 13, 2020)
Science

Schumer hosts cannabis meeting with other lawmakers (Newsletter: February 2, 2023)

February 2, 2023
Aurora Cannabis Inc. (TSE:ACB) Receives Average Recommendation of “Hold” from Analysts
Science

Aurora Cannabis (ACB) Scheduled to Post Quarterly Earnings on Thursday

February 2, 2023
The White House Is Reviewing CBD And Marijuana Research Guidance From FDA
Science

What New Federal Cosmetics Rules Mean For Products Made With CBD And Other Cannabis Derivatives (Op-Ed)

February 1, 2023
Load More
Next Post
Porn and Pot Surged During the Pandemic—But Which Performed Best?

Porn and Pot Surged During the Pandemic—But Which Performed Best?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Updates

Investing In Cannabis Stocks – Soft Secrets

Investing In Cannabis Stocks – Soft Secrets

March 20, 2023
Hope for Hyperemesis Gravidarum Patients

Hope for Hyperemesis Gravidarum Patients

March 20, 2023
Cómo Hacer Clones De Marihuana

Cómo Hacer Clones De Marihuana

March 20, 2023
Cannabis Public Health Harms Debunked – Cannabis | Weed | Marijuana

Cannabis Public Health Harms Debunked – Cannabis | Weed | Marijuana

March 20, 2023
April 20 Becomes a Paid Holiday for Employees at a Massachusetts Cannabis Company

April 20 Becomes a Paid Holiday for Employees at a Massachusetts Cannabis Company

March 20, 2023
CBDBuzzz.com

This is an online news portal that aims to share latest news about "News, Culture, Science, Health, Shop" and much more stuff like that. Feel free to get in touch with us!

Recent News

Investing In Cannabis Stocks – Soft Secrets

Investing In Cannabis Stocks – Soft Secrets

March 20, 2023
Hope for Hyperemesis Gravidarum Patients

Hope for Hyperemesis Gravidarum Patients

March 20, 2023

Subscribe Now

Loading
  • Contact Us
  • Privacy Policy

© 2020 matans3.sg-host.com - All rights reserved!

No Result
View All Result
  • Home
  • News
  • Culture
  • Science
  • Health
  • Videos
  • Shop

© 2020 matans3.sg-host.com - All rights reserved!